Background: Inotuzumab ozogamicin (InO) is an anti-CD22 antibody drug conjugate that is FDA approved for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia (B-cell ALL). Liver toxicity, particularly veno-occlusive disease (VOD) was the most important grade 3 toxicity in the Phase III INO-VATE study of InO, driven by the active cytotoxic agent calicheamicin conjugated to InO, especially in pts who underwent subsequent stem cell transplantation (SCT) (Kantarjian et. al, NEJM 2016). However proper assessment of liver function and fibrosis through elastographic measurements might predict the risks of subsequent liver toxicity with InO. Aim: We aimed to study the extent of liver toxicity, including VOD, in pts treated with InO and its correlation to baseline liver elastography. Methods: Pts with B-cell ALL treated with InO containing low intensity combination regimen [miniCVD-InO- blinatumomab-rituximab (previously published; Jabbour et. al. Cancer 2018)] as part of a clinical trial (NCT01371630) underwent baseline liver elastography and were prospectively monitored for any evidence of liver toxicity, including VOD. Elastography was done within 4 weeks prior to the first infusion of InO and liver stiffness was stratified based on the median shear wave velocity (SWV) using the acoustic radiation force impulse (ARFI) technique. Elastographic median SWV >1.7 m/s was considered as evidence of definite liver fibrosis. We captured the patient characteristics, history of known liver disorders, baseline liver function tests, total dose of InO administered and any subsequent liver toxicities including VOD. Any antecedent or subsequent history of SCT was noted; liver toxicity was graded according to the NCI CTCAE, v5. The dose of InO was capped at a cumulative maximum of 2.7mg/m2 of body surface area (administered in fractionated doses) and all pts received concurrent ursodiol prophylaxis with InO. Results: From Jan 2018- April 2022, 50 consecutive pts treated with the above regimen and with baseline elastography reports available as part of the research protocol were analyzed. The median age of the pts was 54.9 years (yrs) (range, 21.7-87.7 yrs) and only 1 pt had a known prior liver ailment of non-alcoholic fatty liver disease (NAFLD). Baseline characteristics are mentioned in Table 1. The median InO dose received by the pts were 1.5 mg/m2 (range, 0.9-2.7 mg/m2) and only 11 pts (22%) received the maximum cumulative InO dose of 2.7 mg/m2. A total of 11 pts (22%) had a baseline maximum SWV >1.7 m/s which radiologically corresponds to possible compensated advanced chronic liver disease (cACLD) and no pts had a SWV >2.1 m/s (corresponds to clinically significant portal hypertension; CSPH). All pts achieved CR/CRi as best response and 14 pts (28%) underwent consolidative SCT. Only one pt developed a VOD of the liver, diagnosed based on clinical and radiological findings, at D+60 post haploidentical-SCT with Flu/Mel140 conditioning and post-transplant cyclophosphamide. This pt had normal baseline liver elastography and had received a cumulative InO dose of 1.5 mg/m2. Another 5-pts (10%) had ≥ grade 3 liver toxicity (1 pt with hyperbilirubinemia and 4 pts with ALT elevation), all of whom had baseline SWV <1.7 m/s on elastography. On regression analysis using age, cumulative InO dose, baseline values of total bilirubin, ALT and INR, and SWV cutoffs as covariates, no factor significantly affected the risks of ≥ grade 3 liver toxicity. After adopting the use of reduced dose fractionated InO administration regimen, routine ursodiol prophylaxis and avoiding peri-transplant azole antifungal prophylaxis in InO exposed B-cell ALL pts at our center, the frequency of liver toxicites including VOD has significantly reduced compared to the 11% rate of VOD described in the INO-VATE study. With these improvisations reducing the overall frequency of InO induced liver toxicity, the positive predictive value of a pre-InO elastography to envisage the risks of subsequent VOD and other liver toxicity in these pts is highly limited. Conclusion: In a prospectively monitored group of pts of B-cell ALL treated with fractionated InO containing combination regimen, baseline liver elastography did not predict the risk of subsequent liver toxicity. Sequential liver elastographies to monitor dynamic changes in SWV needs to be analyzed in future studies to further assess its predictive role for InO induced liver toxicity. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal